With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.The 2nd Next Generation Kinase Inhibitors Summit is the only industry-focused conference devoted to using novel kinase biology in drug development and innovating current programs to produce the next generation of kinase inhibitor drugs that can demonstrate effective and long-lasting clinical responses in oncology and other fields.Now with a deeper exploration of Assay Development tools to improve experimental accuracyAI/ML Integration into discovery and development to accelerate the developmentGreater consideration of new therapeutic opportunities in novel disease areas to expand horizons